Vitamin K2 (± Vitamin D) and Coronary Artery Calcification
Mechanism of Action Vitamin K2 is hypothesized to inhibit arterial calcium deposition by activating Matrix Gla Protein (MGP), a potent inhibitor of vascular calcification. This mechanistic link has driven research into using high-dose Vitamin K2 (menaquinone) to slow the progression of Coronary Artery Calcium (CAC).
Key Clinical Evidence
- 2023 Meta-Analysis (14 RCTs, n=1,533):
- Finding: Vitamin K supplementation demonstrated a statistically significant deceleration of CAC progression compared to placebo.
- Data: The pooled mean difference in annual CAC change was –17.3 Agatston units (95% CI: –34.2 to –0.56; p = 0.04).
- Safety: The safety profile was comparable to placebo.
- The Hasifić et al. Trial (2023) – Largest RCT to Date:
- Design: Randomized 389 older men with high vascular calcification to receive high-dose K2 (720 µg/day MK-7) + Vitamin D (1000 IU) vs. placebo for 2 years.
- Overall Cohort Results: Both groups saw CAC increases (+203 AU for treatment vs. +254 AU for placebo). The difference was not statistically significant (p = 0.089).
- High-Risk Subgroup (Baseline CAC ≥400): Supplementation significantly slowed CAC growth compared to placebo (+288 AU vs. +380 AU; p = 0.047).
- Clinical Outcomes: There were significantly fewer clinical events in the K2/Vitamin D arm (1.9% vs. 6.7%; p = 0.048), though the study was not powered to detect hard clinical endpoints.
- Supporting & Conflicting Data:
- Positive Signal: A smaller study on patients with moderate CAC (100–400) indicated that 360 µg/day of MK-7 slowed progression by roughly 6% over two years, compared to a 12% progression in the placebo group.
- Null Results: Some trials, particularly within chronic kidney disease (CKD) populations, have shown no benefit regarding calcification scores.
Current Consensus & Future Outlook While Vitamin K2 is safe and biologically plausible, evidence remains mixed. It appears most effective in slowing progression among patients with severe existing calcification (CAC ≥400), mirroring findings seen in statin therapy.
It is not yet a standard recommended therapy for high CAC, but it remains an area of active investigation (e.g., the ongoing 400-patient BASIK2 trial in Denmark) to definitively determine if K2 retards arterial calcification.
References
- Effect of Vitamin K Supplementation on Coronary Artery Calcification (2023 Meta-Analysis): Link to frontiersin.org (frontiersin.org)
- Hasifić et al. (2023) - Effects of Vitamin K2 and D on CAC Progression: Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT. (JACC Adv, 2023)
- Menaquinone-7 Slows Progression of Coronary Calcification (Small Study):MENAQUINONE-7 SLOWS DOWN PROGRESSION OF CORONARY ARTERY CALCIFICATION. A RANDOMIZED,… (Journal of Hypertension, 2025)
- Null Results in Chronic Kidney Disease Trials:Randomized Controlled Clinical Trial of the Effect of Treatment with Vitamin K2 on… (Kidney Int Rep, 2023)
- BASIK2 Trial Protocol (Ongoing Denmark Study):Effects of vitamins K2 and D3 supplementation in patients with severe coronary artery… (BMJ Open, 2023)
